DrugPatentWatch Database Preview

Details for Patent: 8,476,010

Which drugs does patent 8,476,010 protect, and when does it expire?

Patent 8,476,010 protects DIPRIVAN and is included in one NDA.

Protection for DIPRIVAN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one patent family member in one country.

Summary for Patent: 8,476,010

Title:	Propofol formulations with non-reactive container closures
Abstract:	A sterile pharmaceutical composition for parenteral administration of propofol, said composition comprising propofol, optionally albumin, and less than about 10% by weight solvent for propofol, wherein said composition is stored in a container having a closure wherein said closure is inert to propofol.
Inventor(s):	Desai; Neil P. (Pacific Palisades, CA), Yang; Andrew (Rosemead, CA), Ci; Sherry Xiaopei (San Marino, CA)
Assignee:	APP Pharmaceuticals LLC (Schaumburg, IL)
Application Number:	10/616,709
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,476,010
Patent Claim Types: see list of patent claims	Composition; Dosage form;

Drugs Protected by US Patent 8,476,010

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Fresenius Kabi Usa	DIPRIVAN	propofol	INJECTABLE;INJECTION	019627-002	Jun 11, 1996	AB	RX	Yes	Yes	➤ Sign Up	➤ Sign Up			Y		➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 8,476,010

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
9,072,656	Propofol formulations with non-reactive container closures	➤ Sign Up
8,889,346	Propofol formulations with non-reactive container closures	➤ Sign Up
9,072,655	Propofol formulations with non-reactive container closures	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 8,476,010

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
World Intellectual Property Organization (WIPO)	2005007131	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 8,476,010

For more information try a trial or see the plans and pricing